Control arm overperformance in phase 3 oncology clinical trials
Cancer · 2026
DOI: 10.1002/cncr.70306 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cancer, 2026. Verfasst von Ansel P Nalin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Randomized Controlled Trials as Topic, Research Design, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Andrew Sabin Family Foundation.
Abstract (Originalsprache)
Background
In randomized clinical trials (RCTs), anticipating control arm outcomes is important for power calculations and enrollment goals. Unexpected overperformance of the control arm can underpower RCTs. The objective of this study was to estimate the prevalence of control arm overperformance in phase 3 oncology RCTs.
Methods
The authors conducted a meta‐epidemiological study of two‐arm, superiority‐design, phase 3 oncology RCTs. They reviewed articles/publications and protocols for power calculations, justification, and outcomes. Control arm performance was measured as the ratio of observed control arm outcomes relative to pretrial estimates, and overperformance was defined as a 10% improvement.
Results
In total, 385 RCTs met inclusion criteria. The primary end point was overall survival (OS) in 134 RCTs (35%). Of 311 RCTs (81%) that provided a pretrial estimate for control arm performance, 138 RCTs (44%) cited a justification for the estimate. Greater than expected control arm performance was associated with lower odds of meeting the primary end point (adjusted odds ratio, 0.989; 95% confidence interval, 0.981–0.998; p = 0.015). Of 244 RCTs that were evaluable for control arm performance, 104 (43%) exhibited overperformance. RCTs that used OS as a primary end point were more likely to exhibit control arm overperformance compared with RCTs that used other primary end points (56% vs. 33%; adjusted odds ratio, 2.43; 95% confidence interval, 1.42–4.15; p = .001).
Conclusions
Control arm overperformance is common in phase 3 oncology RCTs and is associated with trial outcomes, suggesting an effect on study power. Because overperformance appears to be especially prevalent when OS is the primary end point, the effects of postprogression therapies on OS may be underappreciated. Alternative strategies for designing trials should be considered for reliable estimation of treatment effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Radiation Oncology, Stanford University, Stanford, California, USA.
- Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Ansel P Nalin, Pavlos Msaouel, Ramez Kouzy, Joseph Abi Jaoude, Avital M Miller, Ethan B Ludmir, Alexander D Sherry
Förderung
- NCI NIH HHS
- Andrew Sabin Family Foundation
Zitieren
APA
Nalin, A. P., Msaouel, P., Grippin, A. J., Kouzy, R., Abi Jaoude, J., Lin, T. A., Miller, A. M., Meimoun, N. S., Ludmir, E. B., & Sherry, A. D. (2026). Control arm overperformance in phase 3 oncology clinical trials. Cancer. https://doi.org/10.1002/cncr.70306
Vancouver
Nalin AP, Msaouel P, Grippin AJ, Kouzy R, Abi Jaoude J, Lin TA, et al. Control arm overperformance in phase 3 oncology clinical trials. Cancer. 2026. doi:10.1002/cncr.70306
BibTeX
@article{Nalin2026,
author = {Nalin, Ansel P and Msaouel, Pavlos and Grippin, Adam J and Kouzy, Ramez and Abi Jaoude, Joseph and Lin, Timothy A and Miller, Avital M and Meimoun, Noah S and Ludmir, Ethan B and Sherry, Alexander D},
title = {Control arm overperformance in phase 3 oncology clinical trials},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70306}
}
EUVIMED